| InChIKey | YEAXWAGAAYUUBX-JVTOQCAZSA-N |
| Inchi | InChI=1S/C184H282N50O60S.C2H4O2/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102;1-2(3)4/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194);1H3,(H,3,4)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-;/m0./s1 |
| SMILES | S(C)CC[C@@H](C(N[C@@H](CCC(=O)O)C(N[C@@H](CCC(=O)O)C(N[C@@H](CCC(=O)O)C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@@H](CCC(=O)O)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(NCC(NCC(N1CCC[C@H]1C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N1CCC[C@H]1C(N1CCC[C@H]1C(N1CCC[C@H]1C(N[C@H](C(N)=O)CO)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H](C)CC)=O)=O)CC(C)C)=O)CCCNC(=N)N)=O)C(C)C)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC(=O)O)NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC1=CC=CC=C1)NC([C@H]([C@@H](C)O)NC(CNC([C@H](CCC(=O)O)NC(CNC([C@H](CC1=CNC=N1)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C)=O |
| LogP | -2.07850 |
| PSA | 1812.35000 |
| 精确分子量 | 4244.05000 |
| 用途 | 1、醋酸艾塞那肽可用作肠降血糖素。 |
1.
Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas
Thomas J. Clough,Nicoleta Baxan,Emma J. Coakley,Charlotte Rivas,Lan Zhao,Isabelle Leclerc,Aida Martinez-Sanchez,Guy A. Rutter,Nicholas J. Long Dalton Trans. 2020 49 4732
2.
The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers
Neha Shrestha,Oriane Bouttefeux,Kevin Vanvarenberg,Patrik Lundquist,Juan Cunarro,Sulay Tovar,Georgiy Khodus,Ellen Andersson,?sa V. Keita,Carlos Gonzalez Dieguez,Per Artursson,Véronique Préat,Ana Beloqui Nanoscale 2018 10 603
3.
Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
Jan Pawlas,Timo Nuijens,Jonas Persson,Thomas Svensson,Marcel Schmidt,Ana Toplak,Mikael Nilsson,Jon H. Rasmussen Green Chem. 2019 21 6451
4.
Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects
Ning Wang,Xuanchen Liu,Lei Shi,Yanwu Liu,Shuo Guo,Wenwen Liu,Xiaokang Li,Jingru Meng,Xue Ma,Zheng Guo Biomater. Sci. 2020 8 1604
5.
In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein
Lian Lu,Xiaoqing Su,Yantai Wang,Yi Luo,Jun Yang,Li Xie,Xuefeng Gao,Yaru Ma,Yaomei Tian,Fengjiao Yuan,Gu He,Bailing Zhou,Yingzi Fan,Xueyan Zhang,Rong Huang,Ying Ka Lam,Lin Jiang,Hua Dai,Qian Zhao,Xiaoyang Liao,Li Yang RSC Adv. 2017 7 54178
6.
Revisiting amino acids and peptides as anti-glycation agents
H. Chilukuri,M. J. Kulkarni,M. Fernandes Med. Chem. Commun. 2018 9 614
7.
Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP-1 on type 2 diabetes mellitus via the gut–pancreas–liver axis
Hong Hu,Jie Luo,Ying Liu,Hongyu Li,Rui Jin,Shengjie Li,Jing Wei,Hong Wei,Tingtao Chen Food Funct. 2023 14 3179
8.
Glucagon-like peptide-1 loaded phospholipid micelles for the treatment of type 2 diabetes: improved pharmacokinetic behaviours and prolonged glucose-lowering effects
Xu Cui,Qinghua Meng,Yingying Chu,Xiaoke Gu,Yan Tang,Feng Zhou,Yingying Fei,Junjie Fu,Jing Han RSC Adv. 2016 6 94408
9.
Exenatide loaded PLGA microspheres for long-acting antidiabetic therapy: preparation, characterization, pharmacokinetics and pharmacodynamics
Yutong Wang,Ting Sun,Yue Zhang,Birendra Chaurasiya,Liping Huang,Xi Liu,Jiasheng Tu,Yerong Xiong,Chunmeng Sun RSC Adv. 2016 6 37452
10.
Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide
Aihong Zhang,Yin Lin,Shirly Nong,Wei Zhao,Mei Dong RSC Adv. 2020 10 25013
